Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."
2026-07-18 13:30
•Lee Samaha •The Motley Fool
••• • Axe Capital view
Viking Therapeutics: Too Soon to Jump In
Wall Street loves Viking Therapeutics’ weight-loss drug, but long trial timelines and side effect worries suggest caution.
Viking Therapeutics is drawing big bullish bets thanks to VK2735, a weight-loss drug that could outperform current treatments. Wall Street’s target price implies massive upside from today’s levels. But the catch is the timeline: key phase 3 trial results are years away, late 2027 or 2028. For South African investors, the biotech story feels a world apart, with no direct exposure on the JSE. Instead, consider the impact on USD/ZAR, as a prolonged North American biotech rally could attract risk appetite to the dollar, keeping the rand under pressure. Given the drug’s potential side effects seen in early trials, enthusiasm should be tempered. This looks like an opportunity for patient traders rather than an urgent buy. If the market’s optimism fades or trial outcomes disappoint, the stock could pull back sharply. this is just my opinion and not financial advice
I would watch Viking Therapeutics from the sidelines, and for rand-based investors, keep an eye on USD/ZAR strength amid global biotech sentiment. Avoid buying VKTX outright on the dip until phase 3 data is closer or oral tolerability concerns clear up.
- VKTX
- USD/ZAR
- Phase 3 trial delays or failures
- Unresolved tolerability issues causing investor sell-off
4/10
Wall Street analysts are bullish on Viking Therapeutics (VKTX), with a consensus price target of $91 representing a potential 150% return. The optimism centers on VK2735, a dual-formulation weight-loss drug showing promising phase 2 efficacy data. However, key phase 3 results won't arrive until late 2027-2028, and some phase 2 oral trial tolerability concerns exist. Cautious investors may want to wait for upcoming maintenance trial results before investing.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Lee Samaha
Categories: Equities, Earnings, Healthcare
Tickers: VKTX
Sentiment: Positive - Wall Street consensus is highly bullish with a $91 price target (150% upside from current $37). The lead drug VK2735 shows promising phase 2 efficacy data with steeper weight loss velocity than competitors. However, sentiment is tempered by tolerability concerns from oral phase 2 trials and the long timeline until phase 3 results (late 2027-2028), suggesting a cautiously optimistic outlook rather than strongly positive.
Keywords: Viking Therapeutics, VK2735, weight-loss drug, phase 3 trials, biotech, GLP-1, stock dip, clinical trials
Insights:
- VKTX: Positive: Wall Street consensus is highly bullish with a $91 price target (150% upside from current $37). The lead drug VK2735 shows promising phase 2 efficacy data with steeper weight loss velocity than competitors. However, sentiment is tempered by tolerability concerns from oral phase 2 trials and the long timeline until phase 3 results (late 2027-2028), suggesting a cautiously optimistic outlook rather than strongly positive.